Developing new drugs to fight drug-resistant tuberculosis
Unraveling the spectrum of intrabacterial amide hydrolysis to develop new classes of pyrazinoic acid prodrugs against pyrazinamide resistant Mycobacterium tuberculosis
['FUNDING_R01'] · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · NIH-11107921
This study is looking at how certain bacteria can help create new medicines for tuberculosis, especially for the tough strains that don’t respond to current treatments, so we can find better options for patients dealing with this challenging illness.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUTGERS BIOMEDICAL AND HEALTH SCIENCES (nih funded) |
| Locations | 1 site (Newark, UNITED STATES) |
| Trial ID | NIH-11107921 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how certain bacteria can break down specific compounds to create new medications for tuberculosis, particularly for strains resistant to current treatments. The team will investigate the mechanisms by which Mycobacterium tuberculosis can resist existing drugs and explore alternative compounds that can effectively target these resistant strains. By analyzing the bacterial enzymes involved in drug activation, the research aims to design new prodrugs that can be more effective against resistant tuberculosis. This work is crucial for improving treatment options for patients suffering from this global health crisis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those with strains resistant to standard treatments.
Not a fit: Patients with non-tuberculosis infections or those who do not have drug-resistant tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for tuberculosis, especially for patients with drug-resistant strains.
How similar studies have performed: Previous research has shown promise in developing new treatments for drug-resistant tuberculosis, indicating that this approach could yield significant advancements.
Where this research is happening
Newark, UNITED STATES
- RUTGERS BIOMEDICAL AND HEALTH SCIENCES — Newark, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALLAND, DAVID — RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- Study coordinator: ALLAND, DAVID
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.